Keryx Biopharmaceuticals Earnings: Here’s Why Shares are Up Now

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.13%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Keryx Biopharmaceuticals Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.03 in the quarter versus EPS of $-0.13 in the year-earlier quarter.

Revenue: Was the same at $7 million as the year-earlier quarter.

Actual vs. Wall St. Expectations: Keryx Biopharmaceuticals Inc. reported adjusted EPS loss of $0.03 per share. By that measure, the company missed the mean analyst estimate of $-0.01. It beat the average revenue estimate of $5.83 million.

Quoting Management: Ron Bentsur, the Company’s Chief Executive Officer, said, “Following the announcement of top-line data, we are now focusing our efforts and resources toward the pending NDA and MAA submissions. We are also progressing with the U.S. Phase 2 CKD study, for which we expect to report top-line data in the third quarter of 2013.”

Key Stats (on next page)…